In news that seems like it just might lead to a strange new superhero, Japanese scientists say cultured human muscle cells can stay swole with an injection of, well, bear serum. The secret, according to a press release from the University of Hiroshima, is bears’ ability to hibernate for extended periods of time without losing muscle...
Month: <span>July 2022</span>
Post
When to Treat Low Testosterone in Diabetes and Obesity
Ute Eppinger July 15, 2022 Men with type 2 diabetes are at higher risk for testosterone deficiency. And in turn, hypogonadism is commonly associated with metabolic syndrome or type 2 diabetes. However, this does not imply a specific need for action, as Stephan Petersenn, MD, media spokesperson for the German Society of Endocrinology (Deutschen Gesellschaft...
Post
A tear-soluble contact lens with silicon nanoneedles to treat eye diseases
XpressCredit: Unsplash/CC0 Public Domain A team of researchers from Purdue University and the University of Michigan, both in the U.S., working with colleagues from Hanyang University, Hongik University and the Kumoh National Institute of Technology, all in the Republic of Korea, has developed a type of contact lens with embedded nanoneedles for treating eye diseases....
Post
How elephants avoid cancer – and we could too
By Rich Haridy July 17, 2022 Elephants were found to have 20 copies of a cancer-suppressing gene, while humans only have one copy Depositphotos An exciting new study from an international team of scientists has shed some light on exactly why elephants, one of the biggest animals on the planet, paradoxically experience unusually low rates...
Post
Código Promocional Codere Para México Por Todo El 202
Bono Codere En 2023 Recibo De Bienvenida Sobre $3000 Pesos Content ¿qué Necesito Para Registrarme Y Obtener Este Bono Codere? Codere ¿cómo Ganar Apuestas Deportivas? Más Información De Codere México Bono Codere Del 200% Hasta $3, 000 Mxn Código Promocional Codere Login Sobre Codere Apuesta Segura En Codere Mx Otras Promociones ¿qué Deportes Puedo Encontrar...
Post
Nitazoxanide drug found to be a potent inhibitor of several human coronaviruses
By Neha Mathur Jul 18 2022 Reviewed by Aimee Molineux In a recent study posted to the bioRxiv* pre-print server, researchers evaluated the activity of nitazoxanide against human coronaviruses (HCoVs). Study: Nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on viral spike glycoprotein. Image Credit: StudioMolekuul/Shutterstock. Background Identified first in the 1960s, HCoVs...
Post
DISABILITY COMPENSATION MAY IMPROVE VETERANS’ HEALTH
A large study comparing Vietnam War-era military veterans who became eligible for disability compensation with ineligible veterans found that eligibility for compensation was associated with substantial reductions in hospitalizations—an important metric of overall health. The longer the eligible veterans received disability payments, the greater the decline in hospitalizations was among that group, the researchers found. The study,...
Post
PEOPLE WITH UNDERACTIVE THYROID MAY FACE HIGHER DEMENTIA RISK
The risk of developing dementia is even higher for people whose condition required thyroid hormone replacement medication, the researchers report. Hypothyroidism occurs when the thyroid gland doesn’t make enough thyroid hormones, which can slow metabolism. Symptoms include fatigue, weight gain, and sensitivity to cold. “In some cases, thyroid disorders have been associated with dementia symptoms that can...
Post
WIRELESS TECH ACTIVATES FLY BRAIN CIRCUITS IN UNDER A SECOND
As reported in Nature Materials, researchers used magnetic signals to activate targeted neurons that controlled the body position of freely moving fruit flies in an enclosure. “To study the brain or to treat neurological disorders the scientific community is searching for tools that are both incredibly precise, but also minimally invasive,” says study author Jacob Robinson,...
Post
Fewer relapses in MS with off-label drug
Patients with multiple sclerosis (MS) treated with the rituximab had a significantly lower risk of relapse than MS patients receiving standard treatment. This has been shown in a phase 3 clinical trial by researchers at Karolinska Institutet and Danderyd Hospital in Sweden published in The Lancet Neurology. Rituximab is not approved as an MS drug, but has...